Introduction
Aggressive non-Hodgkin's lymphomas have a very poor prognosis unless treated with chemotherapy. Combination chemotherapy regimens such as MOPP or BACOP can cure over a third of patients with diffuse histiocytic lymphoma.1'2 However, the initial promise of CHOP, which was reported to produce complete remission in almost 60% of patients with aggressive lymphomas was not realised because almost 50% of patients relapsed within the first 12 months of stopping chemotherapy.3 Further innovation and increasing the intensification of combination chemotherapy programmes have increased the proportion of patients entering complete remission and it should now be feasible to cure between 60-70% of all patients with aggressive lymphomas. [4] [5] [6] However, the majority of data generated from lymphoma studies has emanated from the USA and usually from the specialized centres. [1] [2] [3] [4] [5] [6] Results from the United Kingdom, although confirming the ability to cure aggressive non-Hodgkin's lymphoma, have not reproduced the high response rates reported from the United States.7
The purpose of the present review was to establish the long-term outcome for patients with aggressive lymphomas receiving combination chemotherapy in the West of Scotland. The majority of data came from one centre and there was no patient selection for chemotherapy. 
Patients and methods

Between
Results
Response to chemotherapy
The minimum follow-up for patients in this study was 33 months, ranging to a maximum of 96 months. Complete remission (CR) was obtained in 29 (55%), partial remission (PR) in 20 (38%) and 4 (7%) patients had progressive disease (PD) ( Table III) .
The median number of pulses of chemotherapy required to obtain CR was four, with a range from 1-6. Of the 29 patients in CR: 17 had DH, eight had DM, two had DU and one had DPDL; four were stage I, one was stage II, 11 were stage III and 13 were stage IV; 15 had no symptoms and 14 had 'B' symptoms. Eleven (21 %) patients are alive and disease free, nine patients have relapsed and died and five patients died of infection while neutropenic but in CR. Causes of infective deaths were bronchopneumonia in three and septicaemia in two. Non-malignant causes of death in CR were: a subdural haematoma in an 80 year old patient offchemotherapy, congestive cardiac failure in a 61 year old with ischaemic heart disease, a cerebrovascular accident in a 60 year old and pulmonary embolus in a 60 year old. All of these diagnoses were confirmed at post-mortem, at which there was no evidence of lymphoma. Median time to relapse was 10 months, range 5-36 months (Figure 1 ). The latest Time (months) Figure 2 Survival of patients according to response to chemotherapy.
Six patients (11%) developed platelet counts of < 50 x IO'/l but only two patients required platelet transfusions and there were no haemorrhagic deaths. All patients receiving adriamycin-containing combinations and four patients (29%) receiving CVP developed complete alopecia. There was no hair loss with MVPP. Neurotoxicity was only encountered with the regimens containing vincristine, characterized by mild paraesthesia which was common (68%), but there were no serious neurological sequelae. It is not possible to comment on the emetogenicity of these regimens; a variety ofanti-emetics were used and there was no formal documentation of nausea and vomiting after chemotherapy. Our findings are similar to that reported by the St Bartholomew's hospital group7-they found that only 25% of patients with aggressive lymphomas were disease-free 3-8 years after receiving chemotherapy consisting of adriamycin, vincristine, prednisolone and L-asparaginase, with maintenance methotrexate, cyclophosphamide and 6-mercaptopurine. Nonetheless, one area in which our results could have been improved is in relation to the number of infective deaths which occurred whilst patients were in complete remission. Whereas, one must expect an induction mortality rate for intensive chemotherapy regimens,4 we consider that the 17% mortality rate among our patients achieving complete remission was unacceptably high. Indeed, the high mortality rate in our study probably reflected the lack of intensive support facilities in one centre (Glasgow Royal Infirmary) during the first 5 years of the study.
The small number of patients in this study did not permit an extensive analysis of each individual his-tological subgroup. However, it is now clear that the term 'aggressive lymphoma' embraces a heterogeneous group of tumours,8 and that some tumours such as lymphoblastic lymphoma9 demand more intensive chemotherapy than others. We used the Rappaport classification of non-Hodgkin's lymphoma to present our histological data because this was the usual classification used by our pathologists during the time studied, and also because it allowed us to compare the results with currently published literature. However, we accept that the use ofthis classification is now likely to be superseded by the more modem classifications which take account of the advances made in the immunocytochemical classification of lymphoma.'°N evertheless, this does not invalidate our results since the main purpose of this study was to present the longterm survival of a relatively unselected group of patients with aggressive lymphomas, treated with what would still be regarded as standard chemotherapy.
In conclusion, it is obvious that regimens such as MOPP or CHOP will cure the minority of patients with aggressive lymphomas and that the use of more intensive regimens is indicated, with the caveat that the appropriate supportive facilities are available.
